Upcoming IPOs this week: Integrity Infrabuild, Accretion Pharma SME issues to open, 2 listings scheduled; check list

Upcoming IPOs: Two SME initial public offerings will open for subscription this week. Integrity Infrabuild Developers IPO will open on May 13, while Accretion Pharmaceuticals' initial share sale will hit the primary market on May 14.

Shares of Srigee DLM and Manoj Jewellers will list on the BSE SME platform on Monday, May 12.

Integrity Infrabuild Developers IPO

The net proceeds will be used to fund working capital requirements, capital expenditure to acquire machinery and equipment, and general corporate purposes.

Retail investors can apply for a minimum of one lot size, consisting of 1,200 shares, needing an investment of ₹1,20,000. For high-net-worth individuals, the minimum investment is ₹2,40,000.

Aryaman Financial Services Ltd is the issue's book-running lead manager, while Link Intime India Pvt Ltd is the registrar.

Integrity Infrabuild Developers is an integrated civil contract firm, specialising in contracting and sub-contracting services for government projects, including bridge construction, road construction and building.

Accretion Pharmaceuticals IPO

The initial share sale of Accretion Pharmaceuticals is a fresh issue worth ₹29.75 crore without an offer for sale component. The price band has been set at ₹96 to ₹101 per share.

The objects of the issue are:

• Capital expenditure to buy new equipment, and upgrade existing manufacturing plant
• Repayment of certain borrowings
• Working capital needs
• General corporate purposes

For retail investors, the minimum investment is ₹1,15,200 for 1,200 shares. HNIs need to invest at least ₹2,42,400.

The company has reserved half of the net offer for the qualified institutional buyers, 35% for retail investors and 15% for non-institutional investors.

Accretion Pharmaceuticals manufactures and markets tablets, oral liquid, capsules, ointment, gel, lotion, medicated shampoo, cream, mouthwash and oral powder, among others. The firm also produces pharmaceutical products for various marketers on a loan license or contract manufacturing basis.